RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus [Yahoo! Finance]
Rocket Pharmaceuticals, Inc. (RCKT)
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rocketpharma.com
Company Research
Source: Yahoo! Finance
Rocket Pharmaceuticals RCKT incurred a loss of 38 cents per share in the fourth quarter of 2025, which was narrower than the Zacks Consensus Estimate of a loss of 42 cents. In the year-ago quarter, the company reported a loss of 62 cents per share. In the absence of a marketed product in its portfolio, Rocket Pharmaceuticals did not record any revenues in the fourth quarter. Shares of Rocket Pharmaceuticals were up 6.4% in after-hours trading yesterday following the announcement of the earnings results. The stock has surged 36.7% in the past six months compared with the industry's rise of 22.4%. Zacks Investment Research Image Source: Zacks Investment Research RCKT's Q4 Results in Detail In the reported quarter, general and administrative expenses declined around 42% year over year to $14.7 million. Research and development expenses were $29.3 million, down 21.6% from the year-ago quarter's figure. The decrease reflects more disciplined spending and resource managemen
Show less
Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCKT alerts
High impacting Rocket Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RCKT
News
- Wedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advances [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals (RCKT) had its price target raised by The Goldman Sachs Group, Inc. from $2.00 to $3.00. They now have a "sell" rating on the stock.MarketBeat
- Rocket Pharmaceuticals (RCKT) was upgraded by Lifesci Capital to "strong-buy".MarketBeat
- Rocket Pharmaceuticals (RCKT) had its price target raised by Cantor Fitzgerald from $8.00 to $10.00. They now have an "overweight" rating on the stock.MarketBeat
- Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress [Yahoo! Finance]Yahoo! Finance
RCKT
Earnings
- 2/26/26 - Beat
RCKT
Sec Filings
- 3/2/26 - Form S-3
- 2/26/26 - Form 8-K
- 2/26/26 - Form 10-K
- RCKT's page on the SEC website